{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Check-Cap Ltd. Hits New 52-Week High at USD 3.13
Check-Cap Ltd. has achieved a new 52-week high of USD 3.13, significantly up from its low of USD 0.56. Despite this milestone, the company's one-year performance is down 7.42%. With a market cap of USD 4 million, Check-Cap faces challenges, including negative return on equity and no dividend yield.
Is Check-Cap Ltd. technically bullish or bearish?
As of May 5, 2025, Check-Cap Ltd. is in a mildly bearish trend, indicated by bearish daily moving averages and mixed signals from weekly indicators, suggesting a cautious outlook.
Who are in the management team of Check-Cap Ltd.?
As of March 2022, the management team of Check-Cap Ltd. includes Mr. Steven Hanley (Chairman), Mr. XiangQian Lin (Director), and independent directors Ms. Clara Ezed, Dr. Mary Jo Gorman, and Mr. Yuval Yanai.
What does Check-Cap Ltd. do?
Check-Cap Ltd. is an Israeli clinical-stage medical diagnostics company developing an ingestible imaging system for colorectal cancer screening. It has a market cap of $4.49 million and reported a net loss of $4 million in December 2023.
How big is Check-Cap Ltd.?
As of Jun 18, Check-Cap Ltd. has a market capitalization of 4.49 million, categorizing it as a Micro Cap company, with total assets of 25.02 million and shareholder's funds of 23.69 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
